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applied to Kt/Vurea may be applied to Kt/V of other uremic
retention solutes. In conclusion, it is time to work out a new
theory of the adequacy of dialysis: the paper by Eloot et al.1
has the merit of providing experimental data which allow to
separate the effect of t from that of other variables.
Furthermore, it has the merit of simplifying the conceptual
scenario of adequacy of dialysis and of drawing the focus on
the diffusive mechanisms as the key modality of the removal
of uremic retention solutes.1
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To the Editor: We read with interest the article by Lopez
et al.1 They compared the effects of AMG 641 with calcitriol
(CT) or paricalcitol (PC) alone, and the combination of the
calcimimetic with either CT or PC. We have really found the
paper interesting, but would like to raise some points of
discussion.
Not surprisingly, CT administration induced extraskeletal
calcifications (EC), reduced survival, increased aortic calcium
(Ca) and phosphorous deposition, and enhanced mineral
content in the lung and stomach. Contrary to our
expectations and recent literature data, also PC administra-
tion did not prevent EC and aortic Ca and phosphorous
deposition. Unfortunately, the authors did not comment in
their paper to at least other two new published articles with
opposite results on this topic,2,3 and we believe that the
debate needs to be opened.
It is diffusely agreed that dialysis patients develop
extensive EC, which causes increased arterial stiffness and
high morbidity and mortality because of cardiovascular
events. A variety of risk factors are associated with EC in
dialysis patients (time on dialysis, uremic toxins, history of
diabetes, inflammation), but abnormalities in bone mineral
metabolism may play a critical role.4 In this direction, both
vitamin D receptor activators and calcimimetics represent
new tools in the treatment of secondary hyperparathyroidism
and EC.
In experimental animal models, the limited hypercalcemic
effect of PC results from a lower affinity for vitamin D
receptor in intestine and bone. In addition, PC causes a
selective vitamin D activation and a reduction in intestinal
Ca absorption.5 Recently, an in vitro study demonstrated that
CT increased calcification of vascular smooth muscle cells
cultured in calcification media, but this effect was not present
when cells were incubated with PC.2 Moreover, in an in vivo
study Mizobuchi et al.3 showed that both CT and
doxercalciferol significantly increased the serum Ca and
phosphorous product and aortic Ca content in uremic rats.
In contrast, PC had no effect on EC.
Finally, recent prospective studies demonstrated that
hemodialysis patients receiving low doses of PC intrave-
nously have a reduced mortality risk compared to untreated
patients6 and that PC has a survival benefit over CT.7
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We thank Dr Cozzolino and Dr Brancaccio for their interest
in our recently published article in which we investigated the
effect of calcitriol, paricalcitol, and the research calcimimetic
AMG 641, alone or in combination, on the development of
vascular and other soft tissue calcifications in a rat model of
uremia-associated secondary hyperparathyroidism (HPT).
After completing this study we concluded that the calcimi-
metic AMG 641 reduces parathyroid hormone (PTH)
without inducing extraskeletal calcifications under condi-
tions in which the vitamin D derivatives did.1
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